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Abstract The National Institute for Health and Care
Excellence (NICE) invited the manufacturer of lenalido-
mide (Celgene) to submit evidence of the clinical and cost
effectiveness of the drug for treating adults with
myelodysplastic syndromes (MDS) associated with dele-
tion 5q cytogenetic abnormality, as part of the Institute’s
single technology appraisal (STA) process. Kleijnen Sys-
tematic Reviews Ltd (KSR), in collaboration with Erasmus
University Rotterdam, was commissioned to act as the
Evidence Review Group (ERG). This paper describes the
company’s submission, the ERG review, and the NICE’s
subsequent decisions. The ERG reviewed the evidence for
clinical and cost effectiveness of the technology, as sub-
mitted by the manufacturer to the NICE. The ERG sear-
ched for relevant additional evidence and validated the
manufacturer’s decision analytic model to examine the
robustness of the cost-effectiveness results. Clinical
effectiveness was obtained from a three-arm, European,
randomized, phase III trial among red blood cell (RBC)
transfusion-dependent patients with low-/intermediate-1-
risk del5q31 MDS. The primary endpoint was RBC inde-
pendence for C26 weeks, and was reached by a higher
proportion of patients in the lenalidomide 10 and 5 mg
groups compared with placebo (56.1 and 42.6 vs 5.9 %,
respectively; both p\ 0.001). The option of dose adjust-
ments after 16 weeks due to dose-limiting toxicities or lack
of response made long-term effectiveness estimates unre-
liable, e.g. overall survival (OS). The de novo model of the
manufacturer included a Markov state-transition cost-util-
ity model implemented in Microsoft Excel. The base-case
incremental cost-effectiveness ratio (ICER) of the manu-
facturer was £56,965. The ERG assessment indicated that
the modeling structure represented the course of the dis-
ease; however, a few errors were identified and some of the
input parameters were challenged. In response to the
appraisal documentation, the company revised the eco-
nomic model, which increased the ICER to £68,125 per
quality-adjusted life-year. The NICE Appraisal Committee
(AC) did not recommend lenalidomide as a cost-effective
treatment. Subsequently, the manufacturer submitted a
Patient Access Scheme (PAS) that provided lenalidomide
free of charge for patients who remained on treatment after
26 cycles. This PAS improved the ICER to £25,300,
although the AC considered the proportion of patients who
received treatment beyond 26 cycles, and hence the ICER,
to be uncertain. Nevertheless, the AC accepted a commit-
ment from the manufacturer to publish, once available, data
on the proportion of patients eligible for the PAS, and
believed this provided reassurance that lenalidomide was a
cost-effective treatment for low- or intermediate-1-risk
MDS patients.
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Key Points for Decision Makers
Treatment with lenalidomide is clinically effective
because it is associated with improved transfusion
independence and health-related quality of life.
Due to the crossover design of the trial after
16 weeks, long-term effectiveness estimates were
unreliable and overall survival (OS) was estimated
through an indirect relationship, i.e. lenalidomide
reduces transfusion dependence and patients
becoming transfusion independent have better OS.
The patient access scheme increased uncertainty
around the value of the resulting ICER since it only
benefits patients on treatment beyond 26 cycles and
there was uncertainty on this proportion.
Lenalidomide was accepted under the commitment
of the manufacturer to collect data on the proportion
of patients on treatment beyond 26 cycles. Data
collection by the manufacturer ensures uncertainties
can be addressed when the guidance is reviewed;
however, it does not address any loss in health
benefits for other patients in the National Health
Service (NHS) if it turns out that survival has been
overestimated and that lenalidomide was in fact not
cost effective.
1 Introduction
The National Institute for Health and Care Excellence
(NICE) is an independent organization providing national
guidance on promoting good health and preventing and
treating ill health [1]. The single technology appraisal
(STA) process is designed to provide recommendations and
guidance on a single product, device or other technology
with a single indication. The process covers new tech-
nologies and enables the NICE to produce guidance shortly
after the technology is introduced in the UK. The NICE
Appraisal Committee (AC) obtains relevant evidence from
several sources: the manufacturer’s submission (MS), a
report from the appointed independent Evidence Review
Group (ERG) and advice from consultees (i.e. experts and
other stakeholders). The MS includes a written report and a
mathematical model that describe the clinical and cost
effectiveness of the technology under investigation. The
ERG, an external organization independent of the NICE,
reviews the MS and produces a report. After consideration
of all the relevant evidence, the AC formulates preliminary
guidance in the form of the Appraisal Consultation
Document (ACD) as to whether to recommend the inter-
vention. The stakeholders are invited to comment on this
ACD and the submitted evidence. A subsequent ACD may
be produced or a Final Appraisal Determination (FAD)
issued. The submission of a Patient Access Scheme (PAS)
is allowed in order to allow the NICE to recommend
treatments that would otherwise not have been found to be
cost effective. The PAS is a means of reducing the price of
the drug by some means, e.g. simple discount or other
formula, and has to be agreed by the Department of Health.
This paper presents a summary of the ERG report and the
development of NICE guidance based on the findings of
the AC for the STA of lenalidomide for treating
myelodysplastic syndromes (MDS) associated with dele-
tion 5q (del5q) cytogenetic abnormality. Full details of all
the relevant appraisal documents can be found on the NICE
website [2]. This is one in a series of STA summaries being
published in Pharmacoeconomics [3–8].
2 The Decision Problem
MDS are a heterogeneous group of hematological disorders
in which the bone marrow functions abnormally, causing
peripheral blood cytopenia due to insufficient production of
mature blood cells [9]. MDS can affect red blood cells
(RBCs), white blood cells (WBCs) and platelets, resulting
in anemia, increase in bleeding, infection and disease
transformation to acute myeloid leukemia (AML) [10]. The
quality of life of patients with MDS is impaired due to
symptoms such as fatigue and dyspnea as well as treat-
ments involving hospitalizations with drug administration
and blood transfusions. As reported in 2003, the incidence
is approximately 4 per 100,000 population but rises to[30
per 100,000 in the over 70 years age group [11]. In the UK,
there are approximately 11,200 patients diagnosed with
MDS [12], a condition that is mainly caused by cytogenetic
abnormalities found in marrow cells. The most common
cytogenetic abnormality, present in approximately 15 % of
patients with MDS, is del5q [13].
Currently, there is no active treatment available for
patients with MDS del5q since stem cell transplantations or
treatment with azacitidine are not recommended for this
patient group [11]. Patients receive best supportive care
(BSC), which includes blood transfusions to control
symptoms associated with bone marrow failure and
antibiotics to treat or prevent infection. In addition, growth
factors such as erythropoietin and/or granulocyte-colony
stimulating factors to stimulate the production of RBCs and
WBCs are prescribed.
Lenalidomide was already available in the UK for the
treatment of relapsed refractory multiple myeloma. In 2013
the European Medicines Agency extended the market
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authorization of lenalidomide to include patients with
transfusion-dependent anemia due to low- or intermediate-
1-risk MDS associated with del5q when other therapeutic
options were insufficient or inadequate [14]. Lenalidomide
is an oral therapy that aims to reverse transfusion
dependence.
The NICE developed a scope for the assessment of
lenalidomide, which specified that the clinical and cost
effectiveness of this drug should be established, relative to
BSC for the treatment of patients with transfusion-depen-
dent anemia due to low- or intermediate-1-risk MDS
associated with del5q cytogenetic abnormality with or
without other cytogenetic abnormalities.
3 The Independent Evidence Review Group
Review
Kleijnen Systematic Reviews Ltd (KSR), in collaboration
with Erasmus University Rotterdam, acted as the ERG. The
ERG reviewed the evidence on the product’s clinical and
cost effectiveness among low- or intermediate-1-risk MDS
del5q patients as submitted by the manufacturer (Celgene).
The review embodied three aims:
• to assess whether the MS conformed to the method-
ological guidelines issued by the NICE [1];
• to assess whether the manufacturer’s interpretation and
analysis of the evidence was appropriate;
• to indicate the presence of other sources of evidence or
alternative interpretations of the evidence that could
help to inform NICE guidance.
The ERG critically reviewed the MS, conducted addi-
tional searches, explored the impact of assumptions on the
incremental cost-effectiveness ratio (ICER), revised the
economic model and explored additional scenario analyses.
The ERG review detailed here relates to the evidence
contained in the original MS and additional information
submitted by the manufacturer in response to the clarifi-
cation questions and ACD, which included a PAS.
3.1 Clinical Evidence
The MS included a systematic review of the literature on
the clinical effectiveness of lenalidomide. Evidence on the
efficacy of lenalidomide was extracted from the MDS-004
trial, a phase III, multicenter, randomized, double-blind,
placebo-controlled study [15]. Adult patients with low- or
intermediate-1-risk MDS with del5q, with or without
additional cytogenetic abnormalities and RBC transfusion-
dependent anemia (N = 205) were randomly assigned to
three arms: lenalidomide 10 mg on days 1–21, lenalido-
mide 5 mg on days 1–28, or placebo on days 1–28 for each
4-week cycle. BSC included blood transfusions that were
provided to all transfusion-dependent patients as required.
If dose-limiting toxicities occurred, the dose of lenalido-
mide was reduced. Crossover was allowed at 16 weeks if at
least a minor erythroid response (i.e. a 50 % decrease in
transfusion requirements) was not achieved, and all but 11
patients on the placebo arm crossed over to lenalidomide
5 mg. Before crossover at 16 weeks, two patients (3 %) in
the placebo group, two (2.9 %) in the lenalidomide 5 mg
group and none in the lenalidomide 10 mg group pro-
gressed to AML. The primary endpoint was RBC transfu-
sion independence for C26 weeks, which was reached in
56.1, 42.6, and 5.9 % of patients in the lenalidomide
10 mg, lenalidomide 5 mg, and placebo groups, respec-
tively. Transfusion-independent rates in both lenalidomide
groups were different compared with placebo (p\ 0.001).
Median duration of transfusion independence was not
reached in either lenalidomide group after a median follow
up of 1.55 years. Of the patients who initially received
placebo and crossed over to lenalidomide 5 mg, 30.4 %
progressed to AML, compared with 23.2 % in the 5 mg
group and 21.7 % in the 10 mg group. Median overall
survival (OS) was not statistically significantly different
between the groups, and ranged from 35.5 to 44.5 months.
Significantly higher proportions of treatment-emergent
adverse events (AEs) were reported among patients treated
with lenalidomide compared with placebo-treated patients.
At least one drug-related AE was reported in 42 % of the
placebo group, 87 % in the lenalidomide 5 mg group and
90 % in the lenalidomide 10 mg group. The most frequent
drug-related AEs were neutropenia (15 % in the placebo
group and 74 % in each lenalidomide group) and throm-
bocytopenia (2 % in the placebo group and 32 and 36 % in
the 5 mg and 10 mg groups, respectively).
Health-related quality of life (HRQoL) outcomes were
assessed during the MDS-004 trial using the Functional
Assessment of Cancer Therapy–Anemia (FACT–An)
questionnaire, which was administered at baseline, and
weeks 12, 24, 36 and 48. The EQ-5D was administered at
baseline only. Compared with placebo, treatment with
lenalidomide was associated with improvements in HRQoL
(FACT-An scores) during the initial 12 weeks of therapy.
Improved HRQoL was maintained in patients who
remained on double-blind treatment with lenalidomide.
Among patients who switched from placebo to the
lenalidomide 5 mg group, improved HRQoL was observed.
3.2 Critique of the Clinical Evidence
and Interpretation
According to the ERG, some of the literature searches of
the manufacturer were unnecessarily restrictive. For AEs,
other study designs could have been included and longer-
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term data could have been sought. It was also not clear how
studies were identified for inclusion. Nevertheless, the
ERG was unaware of any relevant trials that had been
missed, and agreed with the manufacturer that the MDS-
004 trial was most likely the best source of clinical evi-
dence for the effectiveness of lenalidomide versus BSC.
Data extraction from the MDS-004 trial was reported for
the intention-to-treat (ITT) population (N = 205) as well
as for the modified ITT (mITT) population (N = 139). The
primary reason for exclusion from the mITT was an
inadequate bone marrow sample, preventing confirmation
of the diagnosis of low- or intermediate-1-risk MDS del5q.
The manufacturer considered the ITT to match more clo-
sely with the daily practice population as defined in the
NICE scope; therefore the rates from this population were
used in the health economic model. Response rates for
lenalidomide were based on the lenalidomide 10 mg group
(60.9 %), while the response rate in the model was 7.5 %
for the placebo group. Nevertheless, the ITT population
included patients not fulfilling the inclusion criteria, i.e.
del5q mutation and bone marrow morphology.
Although serious infections were explicitly mentioned
as a relevant outcome in the NICE scope, reporting on this
outcome in the MS was minimal. Additional data were
obtained from the clinical study report and showed that
serious infections occurred in the lenalidomide groups
twice as often as in the placebo group.
Due to the crossover design after 16 weeks, and dose
reductions of the trial, the chances of detecting attributable
prolonged survival or acceleration of leukemia progression
were limited.
3.3 Cost Effectiveness
The manufacturer submitted a de novo economic evalua-
tion on the cost effectiveness of lenalidomide compared
with BSC in low- or intermediate-1-risk MDS del5q
patients who were transfusion-dependent. An Excel-based
Markov model was developed with 14 health states that
reflected transfusion requirements, iron chelation, pro-
gression to AML, and complications associated with both
transfusion dependency and iron chelation therapy. Patients
responding to treatment became transfusion-independent,
while non-responders remained transfusion-dependent. As
a simplifying assumption, all trial patients who responded,
regardless of timing, were classed as responders from
cycle 1 onwards. Transition probabilities for OS and pro-
gression to AML were assumed to be different for trans-
fusion-dependent and -independent patients, and estimated
based on the initial response for lenalidomide and BSC of
the MDS-004 trial. Response rates for iron chelation ther-
apy and iron overload complication rates were based on the
literature [16, 17].
Lenalidomide treatment (plus BSC) is compared with
BSC, which was also the comparator in the MDS-004
trial. However, BSC in the trial consisted of blood
transfusions only (plus chelation therapy when iron
overload occurred), whereas BSC in the UK may also
include the provision of erythropoietin-stimulating agents
(ESA) or ESA plus granulocyte-colony stimulating fac-
tors (G-CSF). The proportion of patients receiving ESA
in the model was calculated from the proportion of UK
patients in the MDS-004 trial who received ESA prior to
the trial, i.e. 28 %. Of the side effects associated with
lenalidomide, only neutropenia and thrombocytopenia
were included in the model since only these were con-
sidered serious enough by the manufacturer to warrant
inclusion while also being different between the placebo
and lenalidomide arms in the trial. Iron chelation is
initiated to avoid complications associated with iron
overload for transfusion-dependent patients. In the de
novo model, patients received either desferrioxamine or
deferasirox as iron chelation therapy. Since the number
of patients included in the trial was insufficient to obtain
transition probabilities for AML mortality, transition
probabilities were obtained from the adverse risk group
in the article by Wahlin et al. [18]. No half-cycle cor-
rection was applied. The model had a National Health
Service (NHS) perspective and time horizon of 20 years.
Costs and effects were discounted at an annual rate of
3.5 %.
During the MDS-004 trial, quality of life was measured
using the FACT-An at baseline and in weeks 12, 24, 36 and
48. However, the EQ-5D was measured at baseline only
(i.e. when all patients were still transfusion-dependent) and
therefore EQ-5D data for transfusion-independent patients
were not available. Therefore, utility values were obtained
from the study by Szende et al. [19].
Drug acquisition prices were obtained from the British
National Formulary (6 March 2013), while the frequency
of monitoring associated with the initiation of lenalidomide
treatment was based on the summary of product charac-
teristics. Monitoring visits were assumed to occur with a
general practitioner (GP). Costs for lenalidomide were
based on the dosing observed in the MDS-004 trial and
manufacturer’s price quotations. An arbitrary standard
error of 10 % of the mean was assigned to those cost
estimates without a standard error.
The base-case ICER (cost per quality-adjusted life-year
[QALY] gained) was £56,965 per QALY gained. The
probabilistic sensitivity analysis (PSA) showed a 0 %
probability of the ICER being below £30,000 per QALY
gained. Sensitivity analysis revealed that utility values, the
proportion of patients experiencing dose interruptions, and
the curve fitting for progression to AML and overall
mortality were key parameters.
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3.4 Critique of the Cost-Effectiveness Evidence
and Interpretation
The economic model described in the MS was considered,
by the ERG, to meet the NICE reference case to a rea-
sonable extent and was in line with the decision problem
specified in the scope. However, the manufacturer’s
description of the model did not match their own presented
figure. The illogical (e.g. from health-state chelation failure
to no chelation cardiac disease) and missing transitions
(e.g. from health-state transfusion-dependent chelation to
transfusion-independent) were corrected by the ERG.
The ERG challenged some of the assumptions of the
manufacturer and therefore made the following adjust-
ments in the ERG base-case.
• A half-cycle correction was implemented since the first
few cycles showed a very significant redistribution of
patients over the various health states.
• Deferiprone, a third option for chelation therapy, was
included in the model (Table 1). This slightly changed
the costs per cycle for chelation therapy (from £1383 to
£1332) but also influenced the QALYs since adding this
third option increases the proportion of patients
receiving oral instead of intravenous chelation therapy
(from 71 to 94.3 %).
• Standard errors without a standard deviation estimate
were increased from 10 to 20 % of the mean for
adverse events and complications. The standard errors
of 10 % were considered too small by the ERG since
more variation for costs is usually observed.
• A programming error for the initial response rate for
BSC was corrected.
• The effect of G-CSF, in addition to ESA, for nonre-
sponders to BSC was added. The initial response rate
was used in the model of the manufacturer. G-CSF is
only added to ESA for patients who do not respond to
ESA. As a consequence, the model of the manufacturer
did not include the effect of G-CSF for nonresponders
to BSC.
The revised base-case ICER was £62,674 per QALY
gained. The PSA results showed a 0 % probability that the
ICER was below £30,000 per QALY gained.
3.4.1 Remaining Concerns
Utilities were obtained from a study that included broad
health-state descriptions covering a range of health prob-
lems [19]. The manufacturer assumed that these descriptions
adequately described the difference between the transfu-
sion-independent and -dependent health states. However,
this was challenged by the ERG. In addition, the ERG raised
questions on the assumption of similar utility values for
transfusion-dependent and AML health states. The latter
was accepted by the ERG since the impact of the utility value
assigned to AML was minimal. Moreover, a reasonable
alternative for health-state utility values was unavailable.
While the ERG was not entirely convinced that the
definition of BSC fully reflects BSC within the NHS, the
model outcomes were not very sensitive to changes in the
proportion of ESA use.
Table 1 Revised base-case cost-effectiveness analysis, incorporating corrections and amendments identified by the ERG and AC
BSC Lenalidomide Incremental ICER
Cost (£) QALY Cost (£) QALY Cost (£) QALY Cost per QALY
gained (£)
Manufacturer’s base-case analysis 105,726 2.58 156,308 3.46 50,582 0.89 56,965
Corrected confirmed programming errors 104,753 2.59 156,308 3.46 51,555 0.87 59,196
Correcting programming errors dose reduction 104,753 2.59 162,628 3.46 57,875 0.87 66,453
Additional cycle added 104,753 2.59 162,628 3.46 57,875 0.87 66,453
Half-cycle correction 104,052 2.57 160,343 3.43 56,292 0.87 64,929
Chelation therapy deferiprone added 102,270 2.64 158,890 3.49 56,620 0.85 66,346
Cost AML-adjusted 100,655 2.64 157,227 3.49 56,572 0.85 66,289
Response over time (mortality based on
maximum response)
102,839 2.64 153,817 3.45 50,978 0.81 62,773
Cost AEs adjusted 102,836 2.64 153,733 3.45 50,898 0.81 62,674
ERG revised base-case 102,836 2.64 153,733 3.45 50,898 0.81 62,674
Scenario: Monitoring would be undertaken by a
hematologist and progression to AML similar
for lenalidomide and BSC
123,241 2.95 172,307 3.67 49,065 0.72 68,125
ERG Evidence Review Group, AC Appraisal Committee, ICER incremental cost-effectiveness ratio, QALY quality-adjusted life-year, AML acute
myeloid leukemia, AEs adverse events, BSC best supportive care
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Additional scenarios were explored by the ERG and
these revealed that utility and cost parameters related to
AML complications and AEs had little to no effect on the
ICER. The assumption that monitoring occurred with a GP
was challenged by the ERG and therefore adjusted to
monitoring by a hematologist in an additional scenario
analysis, together with revised progression rates to AML
(Table 1).
3.5 Conclusion of the Evidence Review Group
(ERG) Report (Before Implementation
of the Patient Access Scheme [PAS])
According to the ERG, there were two main problems with
the clinical effectiveness data obtained from the MDS-004
trial and described by the manufacturer in the MS. First, the
possibility of crossover after 16 weeks meant that most
long-term effectiveness data were unreliable. Second, data
were reported for two populations—the ITT and an
mITT—and it is not clear how differences between these
populations influenced results.
The manufacturer base-case ICER was £56,965 per
QALY gained, while the ERG base-case, correcting for the
various issues identified, estimated an ICER of £62,674 per
QALY gained.
3.6 ERG Research Recommendations
The ERG concluded that further comparisons of lenalido-
mide and BSC are required in terms of long-term effec-
tiveness, OS, AML progression and incidence of adverse
events. The study on which utilities for the transfusion-
related health states was based did not conform to the
NICE reference case. In order to increase the robustness of
the health economic outcome, a quality-of-life study
among MDS patients would be of great value. Ideally, such
a study would ask transfusion-dependent patients, as well
as patients who have become transfusion-independent, to
fill out the EQ-5D, after which outcomes would be valued
using the UK tariff, which is based on the general popu-
lation [20].
4 Key Methodological Issues
Long-term effectiveness, including survival and progres-
sion to AML, was compromised by the crossover design of
the trial at 16 weeks. The manufacturer stated that survival
of patients with MDS is strongly related to transfusion
dependency. In order to perform a life-time cost-effec-
tiveness analysis, the model linked OS and progression to
AML to transfusion dependency. Therefore, separate time-
to-event curves for people who were transfusion-dependent
or -independent at 8 weeks were estimated from the data of
the MDS-004 trial.
The relationship between survival and transfusion
dependency was supported both by data from the MDS-004
trial (achieving transfusion independence was associated
with a significant reduction in the risk of death [hazard
ratio 0.53; 95 % CI 0.31–0.90; p = 0.019]) and the liter-
ature [21, 22].
Utility values used in the model were not obtained
according to NICE guidelines and, consequently, the
committee needed to decide whether these were accept-
able. The STA described here highlights the difficulties of
relying on a single randomized controlled trial with a
crossover design after 16 weeks. The key issue for a
decision maker is whether or not these clinical and eco-
nomic uncertainties cast sufficient doubt on any patient
gain from taking the drug.
5 National Institute for Health and Care
Excellence Guidance
5.1 Key Issues Considered by the Appraisal
Committee
Regarding effectiveness, the committee concluded that, on
the basis of evidence on transfusion independence and
HRQoL, lenalidomide is a clinically effective treatment for
people with MDS associated with a del5q cytogenetic
abnormality, although uncertainty about whether lenalido-
mide improved survival remained. The committee con-
cluded that the serious adverse events associated with
lenalidomide could be partly managed by a reduction in
dose.
According to the committee, cost-effectiveness esti-
mates from the model were uncertain due to uncertainty in
the survival estimates. In addition, there was uncertainty as
to whether lenalidomide changed the rate of progression to
AML. The committee accepted the utility values reported
by Szende et al. [19] after consulting the patient expert. In
addition, the committee agreed with the adjustments of the
ERG and considered that if the model applied similar rates
of progression to AML for both treatment groups then the
ICER would most plausibly exceed £70,000 per QALY
gained.
5.1.1 Preliminary Guidance (First Appraisal Consultation
Document [ACD])
After considering the initial evidence submitted by the
manufacturer, the ERG report and the testimony of experts
and other stakeholders, the AC concluded that lenalido-
mide could not be recommended for treating transfusion-
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dependent anemia caused by low- or intermediate-1-risk
MDS associated with a del5q cytogenetic abnormality
when other treatments failed.
5.1.2 Response to Preliminary Guidance (First ACD)
and Additional Analysis Submitted
by the Manufacturer
The manufacturer performed a systematic literature review
(July 2013) to better highlight the association between
transfusion independence and survival. The AZA-001 trial
[23], which demonstrated improved survival after becom-
ing transfusion-independent, was considered most con-
vincing by the ERG. Overall, the committee concluded that
while the strength of the relationship over time was
uncertain, it was reasonable for the model to include a
benefit in OS for patients treated with lenalidomide com-
pared with BSC. Based on the additional submitted evi-
dence [24], the AC also concluded that progression to
AML curves should be similar for both lenalidomide and
BSC.
5.1.3 Final Guidance October 2013
Despite the additional analysis of the manufacturer, the
committee did not change the guidance of the first ACD. In
the FAD, they concluded that lenalidomide could not be
recommended for treating transfusion-dependent anemia
caused by low- or intermediate-1-risk MDS associated with
del5q cytogenetic abnormality when other therapeutic
options were insufficient or inadequate. Given the uncer-
tainties, the committee concluded that the most plausible
ICER was above £70,000 per QALY.
5.1.4 The Proposed PAS
The October 2013 FAD for lenalidomide was withdrawn
after the submission of an approved PAS by the manu-
facturer. Under the PAS, the manufacturer would provide
lenalidomide at no cost to the NHS for patients with
transfusion-dependent low- or intermediate-1-risk MDS
with isolated del5q abnormality who continued with
lenalidomide treatment beyond 26 cycles. This PAS is
similar to the existing PAS of lenalidomide for patients
with multiple myeloma. The PAS therefore reduces the
long-term drug costs for patients who receive more than
26 cycles of lenalidomide. A revised version of the model
was submitted and reviewed by the ERG. The deterministic
ICER with the PAS was £25,544. Minor adjustments to the
sensitivity analysis were made by the ERG as these were
also made earlier in the ERG-defined base-case. At a
threshold of £20,000 per QALY, 26.2 % of simulations
were cost effective and, at a threshold of £30,000, 66.6 %
of simulations were cost effective. The ERG reviewed the
proposed PAS and economic model. No additional issues
apart from those stated earlier were identified.
5.1.5 Preliminary Guidance (Second ACD)
The main concerns raised by the AC were uncertainties
with regard to the ICER. These uncertainties included
patient survival, the proportion of patients eligible for the
PAS, and the timing of the PAS rebate. These did not
only influence the point estimate but also the cloud of
possible outcomes around the ICER. For patient survival,
the committee concluded that, despite uncertainty
regarding the strength of the relationship, it was reason-
able to assume a relationship between transfusion inde-
pendence and OS. Therefore, it was plausible that
lenalidomide indirectly improved survival by reducing
transfusion dependence. The committee stated that treat-
ment interruptions were not accounted for in the PAS and
that the proportion of people surviving beyond 26 cycles
in clinical practice was uncertain. Due to the nature of the
PAS, cost reductions were obtained from patients
receiving treatment after 26 cycles. If this proportion is
uncertain in daily practice, the potential cost savings from
the PAS are also subject to uncertainty. As a conse-
quence, the ICER could be much higher. As a response to
the concerns related to the PAS, the manufacturer inclu-
ded treatment interruptions, leading to a longer period of
time before the PAS comes into effect (26 cycles plus
16 days updated the ICER to £25,300). Additional evi-
dence was provided by the manufacturer based on the
MDS-004 trial and real-world data that supported the
proportion of patients on active treatment currently used
in the model (31.9 %). They also conducted an additional
analysis on the proportion of patients eligible for the PAS,
i.e. the proportion of patients on active treatment after 26
cycles. This showed that when 27 % or more patients
reach 26 cycles of treatment, lenalidomide remains cost
effective at a threshold of £30,000 per QALY.
5.2 Final Guidance
After considering the available evidence from the manu-
facturer, the ERG, expert testimony, and other consultees,
the NICE AC decided to recommend lenalidomide for
treating low- or intermediate-1-risk MDS associated with
an isolated del5q cytogenetic abnormality when other
therapeutic options were insufficient or inadequate. The
committee agreed that the ICER was uncertain but accep-
ted that a commitment from the manufacturer to publish
data on the proportion of patients receiving treatment
beyond 26 cycles provided reassurance that lenalidomide
was a cost-effective use of NHS resources.
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6 Conclusions
The STA presented here describes the first treatment
alternative for MDS del5q patients. Clinical evidence was
obtained from a single, randomized, phase III trial with a
crossover design after 16 weeks. The AC decided to accept
lenalidomide as treatment for low- and intermediate-1-risk
MDS del5q patients, although the crossover design of the
trial as well as the PAS increased the uncertainty of the
ICER. A commitment from the manufacturer to collect
data provided reassurance that the uncertainties surround-
ing the ICER can be reassessed when the guidance is
reviewed. Nevertheless, the AC stated that if lenalidomide
was not a cost-effective use of NHS resources, the foregone
health benefits to other NHS patients until the review
cannot be regained. This appraisal illustrated that the AC
can accept a treatment as cost effective under the accep-
tance of a commitment of the manufacturer to collect and
publish data.
This case study saw a PAS accepted by the Ministry of
Health after the initial FAD. While lenalidomide for
treating MDS patients with del5q cytogenetic abnormali-
ties was initially not recommended, the PAS reduced the
ICER substantially from approximately £68,100 to £25,300
per QALY. This changed the recommendation from the
AC. The generalizability of the cost-effectiveness results to
other countries depends on whether such a PAS is also
introduced in these countries, as well as the transferability
of underlying utility and survival estimates.
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